Literature DB >> 10086799

IL4 production and increased CD30 expression by a unique CD8+ T-cell subset in B-cell chronic lymphocytic leukaemia.

D de Totero1, G Reato, F Mauro, A Cignetti, S Ferrini, A Guarini, M Gobbi, C E Grossi, R Foa.   

Abstract

Phenotypic and functional abnormalities within the residual non-B-cell compartment of B-cell chronic lymphocytic leukaemia (CLL) suggest an interaction between tumour cells and host immune effectors. To explore the possibility of a polarized Th1/Th2 response we have studied CD30 antigen expression and the pattern of cytokine production by purified CLL T cells. Activated T cells from CLL patients showed a significant increase in the expression of CD30 compared to normal controls. Accordingly, high levels of soluble CD30 were detected in supernatants from activated T-cell cultures, as well as in CLL serum samples. Messenger RNA for IL4 was found in both resting and, to a greater extent, in activated CLL T lymphocytes. The latter cells were also capable of releasing IL4. Three-colour immunofluorescence analyses revealed a strong CD30 expression in the CD3+/CD8+/CD28- large granular lymphocyte subset, which is considerably expanded in CLL. Production of IL4, as well as expression and release of CD30 by these T cells, was conclusively demonstrated at the clonal level. These findings document an expansion of a peculiar subset of 'Th2-like' cells in CLL, with an increased IL4 production and CD30 expression and release, that are likely to contribute to both the B-cell accumulation and immune-defects characteristic of this disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10086799     DOI: 10.1046/j.1365-2141.1999.01219.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

Review 1.  Th1/Th2 balance in cancer, transplantation and pregnancy.

Authors:  M R Shurin; L Lu; P Kalinski; A M Stewart-Akers; M T Lotze
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Expansion of CD4+ T cells with a cytotoxic phenotype in patients with B-chronic lymphocytic leukaemia (B-CLL).

Authors:  N Porakishvili; T Roschupkina; T Kalber; A P Jewell; K Patterson; K Yong; P M Lydyard
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

3.  Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells.

Authors:  Güllü Görgün; Tobias A W Holderried; David Zahrieh; Donna Neuberg; John G Gribben
Journal:  J Clin Invest       Date:  2005-06-16       Impact factor: 14.808

Review 4.  CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?

Authors:  Hollie J Pegram; Eric L Smith; Sarwish Rafiq; Renier J Brentjens
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

5.  Chronic lymphocytic leukaemia cells drive the global CD4+ T cell repertoire towards a regulatory phenotype and leads to the accumulation of CD4+ forkhead box P3+ T cells.

Authors:  K P Piper; M Karanth; A McLarnon; E Kalk; N Khan; J Murray; G Pratt; P A H Moss
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

Review 6.  Immune reconstitution in chronic lymphocytic leukemia.

Authors:  John C Riches; Alan G Ramsay; John G Gribben
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

7.  Dysregulation of CD30+ T cells by leukemia impairs isotype switching in normal B cells.

Authors:  A Cerutti; E C Kim; S Shah; E J Schattner; H Zan; A Schaffer; P Casali
Journal:  Nat Immunol       Date:  2001-02       Impact factor: 25.606

8.  The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.

Authors:  Matthew D Blunt; Stefan Koehrer; Rachel C Dobson; Marta Larrayoz; Sarah Wilmore; Alice Hayman; Jack Parnell; Lindsay D Smith; Andrew Davies; Peter W M Johnson; Pamela B Conley; Anjali Pandey; Jonathan C Strefford; Freda K Stevenson; Graham Packham; Francesco Forconi; Greg P Coffey; Jan A Burger; Andrew J Steele
Journal:  Clin Cancer Res       Date:  2016-10-03       Impact factor: 12.531

9.  High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.

Authors:  Sina Oppermann; Jarkko Ylanko; Yonghong Shi; Santosh Hariharan; Christopher C Oakes; Patrick M Brauer; Juan C Zúñiga-Pflücker; Brian Leber; David E Spaner; David W Andrews
Journal:  Blood       Date:  2016-06-13       Impact factor: 22.113

10.  CTLA-4 affects expression of key cell cycle regulators of G0/G1 phase in neoplastic lymphocytes from patients with chronic lymphocytic leukaemia.

Authors:  Lidia Ciszak; Irena Frydecka; Dariusz Wolowiec; Aleksandra Szteblich; Agata Kosmaczewska
Journal:  Clin Exp Med       Date:  2015-05-24       Impact factor: 3.984

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.